BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 18924057)

  • 1. [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
    Matthes J; Faust M
    Dtsch Med Wochenschr; 2008 Oct; 133(43):2233-7. PubMed ID: 18924057
    [No Abstract]   [Full Text] [Related]  

  • 2. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
    Langley AK; Suffoletta TJ; Jennings HR
    Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
    Gallwitz B
    Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
    [No Abstract]   [Full Text] [Related]  

  • 4. DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
    Barnett A
    Int J Clin Pract; 2006 Nov; 60(11):1454-70. PubMed ID: 17073841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
    Herman GA; Stein PP; Thornberry NA; Wagner JA
    Clin Pharmacol Ther; 2007 May; 81(5):761-7. PubMed ID: 17392725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The value of incretin based therapies].
    Gallwitz B
    Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
    [No Abstract]   [Full Text] [Related]  

  • 8. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of vildagliptin in the management of type 2 diabetes mellitus.
    Kleppinger EL; Helms K
    Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic use and adverse events of incretin-related drugs].
    Ishikawa M; Yamada Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ
    Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
    Pei Z
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DPP-4 inhibitors in clinical practice.
    Palalau AI; Tahrani AA; Piya MK; Barnett AH
    Postgrad Med; 2009 Nov; 121(6):70-100. PubMed ID: 19940419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three new drugs for type 2 diabetes.
    Drug Ther Bull; 2008 Jul; 46(7):49-52. PubMed ID: 18603639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2].
    Musch A; Heinzl S
    Med Monatsschr Pharm; 2007 Aug; 30(8):282-6; quiz 287-8. PubMed ID: 17879807
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacological sheet. Vildagliptin, oral administration (GALVUS)].
    J Pharm Belg; 2009 Jun; (2):64-6. PubMed ID: 19739530
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.
    Foley JE; Ligueros-Saylan M; He YL; Holst JJ; Deacon CF; Dunning BE; Leone-Jones A; Yu T; Kelley DE
    Horm Metab Res; 2008 Oct; 40(10):727-30. PubMed ID: 18597213
    [No Abstract]   [Full Text] [Related]  

  • 19. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.
    Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch C
    Vasc Health Risk Manag; 2008; 4(4):753-68. PubMed ID: 19065993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin-based therapies in type 2 diabetes: a review of clinical results.
    Bosi E; Lucotti P; Setola E; Monti L; Piatti PM
    Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.